Japanese Regulators Recommend Wyeth-Pfizer's Torisel And Celgene's Revlimid For Approval
This article was originally published in PharmAsia News
Executive Summary
The Second Committee on New Drugs at Japan's Ministry of Health, Labor and Welfare on May 31 recommended Wyeth-Pfizer's Torisel (temsirolimus) and Celgene's Revlimid (lenalidomide) for approval. The approvals came with post-market surveillance requirements and a restricted distribution system in the case of Revlimid
You may also be interested in...
Pfizer, Wyeth Japan Subsidiaries Merge To Become Second-largest Pharma
TOKYO - Pfizer Japan and Wyeth Japan, both of them fully owned by their U.S. parent firms, announced their merger, effective June 1, becoming Japan's second-largest pharmaceutical manufacturer after Takeda Pharmaceutical Co. and expanding Pfizer Japan's cardio and neural product lineup with Wyeth's vaccines
Pfizer Halts Sutent's Phase III in Hepatocellular Carcinoma
Failure is the second in two months for Sutent, which is a lynchpin of Pfizer's oncology strategy.
Pfizer Reports Sutent Safe And Effective In Asians; Forges Alliances With Major Asian Oncology Centers
PERTH, Australia - Pfizer Sept. 21 released data on a Phase IIIb Asian trial of its leading oncology drug multi-kinase inhibitor Sutent, which demonstrated similar effectiveness and tolerability in Asians as in non-Asians